Sugi Predict

Sugi Predict / Compounds / SCHEMBL644526

SCHEMBL644526

SCHEMBL644526

COc1ccccc1/C=C/C(C)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 1.00
▸ NFE2L2 Q16236 2/20 0.77
▸ TFEB P19484 1/20 0.77
▸ MAPT P10636 6/20 0.68
▸ NPC1 O15118 3/20 0.68
▸ LMNA P02545 3/20 0.68
▸ RAB9A P51151 2/20 0.68
▸ BCHE P06276 1/20 0.68
▸ MAPK1 P28482 2/20 0.66
▸ ATM Q13315 1/20 0.66
▸ NPSR1 Q6W5P4 1/20 0.66
▸ TDP1 Q9NUW8 1/20 0.66
▸ LY96 Q9Y6Y9 1/20 0.64
▸ MAOB P27338 3/20 0.62
▸ AR P10275 1/20 0.62
▸ CYP1A2 P05177 3/20 0.60
▸ CYP2D6 P10635 3/20 0.60
▸ HPGD P15428 3/20 0.60
▸ CYP1A1 P04798 2/20 0.60
▸ CYP1B1 Q16678 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL644527 1.00 KDM4E (1.00) KDM4ENFE2L2TFEBMAPTNPC1
SCHEMBL29372147 1.00 KDM4E (1.00) KDM4ENFE2L2TFEBMAPTNPC1
SCHEMBL29805195 0.87 NFE2L2 (1.00) KDM4ENFE2L2TFEBMAPTNPC1
SCHEMBL30307386 0.87 NFE2L2 (1.00) KDM4ENFE2L2TFEBMAPTNPC1
SCHEMBL16403662 0.87 NFE2L2 (1.00) KDM4ENFE2L2TFEBMAPTNPC1
SCHEMBL2744044 0.87 NFE2L2 (1.00) KDM4ENFE2L2TFEBMAPTNPC1
SCHEMBL2744047 0.87 NFE2L2 (1.00) KDM4ENFE2L2TFEBMAPTNPC1
Coumarinic Acid Methyl Ether SCHEMBL714857 0.85 NFE2L2 (0.77) KDM4ENFE2L2TFEBMAPTNPC1
Coumarinic Acid Methyl Ether SCHEMBL29369917 0.85 NFE2L2 (0.77) KDM4ENFE2L2TFEBMAPTNPC1
Coumarinic Acid Methyl Ether SCHEMBL79060 0.85 NFE2L2 (0.77) KDM4ENFE2L2TFEBMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3930849-B1 THIAZOLE DERIVATIVES AS PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2025-02-19 — — EP disclosed
US-20230301984-A1 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-09-28 — — US disclosed
US-20230301984-A1 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-09-28 — — US disclosed
WO-2022158624-A1 NOVEL BENZOPYRAN DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND ANTICANCER COMPOSITION COMPRISING SAME 연세대학교 산학협력단 2022-07-28 — — WO disclosed
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 — — US disclosed
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 — — US disclosed
CN-112266352-B Piperlongumine derivative and preparation method and application thereof 绍兴文理学院 2022-02-08 — — CN disclosed
CN-112266352-A Piperlongumine derivative and preparation method and application thereof 绍兴文理学院 2021-01-26 — — CN disclosed
US-8592430-B2 Quinazolin-oxime derivatives as Hsp90 inhibitors DAC SLR (IT) 2013-11-26 — — US disclosed
EP-2144889-B1 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2012-08-29 — — EP disclosed
WO-2010065881-A2 METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT ZAFGEN CORPORATION (US) 2010-06-10 — — WO disclosed
EP-2144889-A2 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC S.r.l. (IT) 2010-01-20 — — EP disclosed
WO-2009102864-A1 HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE STANFORD UNIVERSITY (US) 2009-08-20 — — WO disclosed
EP-2079747-A1 HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS Pfizer Limited (GB) 2009-07-22 — — EP disclosed
WO-2008142720-A2 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2008-11-27 — — WO disclosed
WO-2008142720-A2 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2008-11-27 — — WO disclosed
US-20080161288-A1 COMPOUNDS PFIZER INC. 2008-07-03 — — US disclosed
WO-2008044127-A1 HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS PFIZER LIMITED (GB) 2008-04-17 — — WO disclosed
US-6177462-B1 Unsaturated oxime ethers and their use as fungicides and insecticides ROHM AND HAAS COMPANY 2001-01-23 — — US disclosed
EP-0936213-A1 Unsaturated oxime ethers and their use as fungicides and insecticides ROHM AND HAAS COMPANY (US) 1999-08-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G KDM4E 4710/4885NFE2L2 3664/4885TFEB 269/4885
US-20080161288-A1 COMPOUNDS ADRB2, ADRB1, ADRA2C KDM4E 4170/4885NFE2L2 326/4885TFEB 1247/4885
US-20230301984-A1 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION ALDH1A2, PDE6D, PDE6C KDM4E 3316/4885NFE2L2 481/4885TFEB 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.